Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 22 of 22 publications.

Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3

Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1

Bhandari NR, Hess LM, Parikh RC, Sireci AN, Krein PM, Kaye JA. Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the United States. Per Med. 2023 Mar;20(2):131-42. doi: 10.2217/pme-2022-0050

Kandzari DE, Weber MA, Poulos C, Coulter J, Cohen SA, DeBruin V, Jones D, Pathak A. Patient preferences for pharmaceutical and device-based treatments for uncontrolled hypertension: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2023 Jan;16(1):e008997. doi: 10.1161/CIRCOUTCOMES.122.008997

Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8

Hoffman V, Xue F, Ezzy SM, Yusuf A, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine treated with prophylactic medications: an observational cohort study. Cephalalgia. 2019 Oct;39(12):1544-59. doi: 10.1177/0333102419856630

Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019 Oct;39(12):1518-34. doi: 10.1177/0333102419851855

Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez-Salas N, Martin-Richard M, Alonso-Orduna V, Vera R, Gallegeo J, Capdevila J, Salud A, Nogue M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol. 2019 Aug 29;5(11):1566-73. doi: 10.1001/jamaoncol.2019.2294

Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, Carozza SE, Sisoudiya SD, Hilsenbeck SG, Janitz AE, Oster ME, Scheuerle AE, Schiffman JD, Luo C, Mian A, Mueller BA, Huff CD, Rasmussen SA, Scheurer ME, Plon SE. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births. JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1215

Kapral MK, Austin PC, Jeyakumar G, Hall R, Chu A, Khan AM, Jin AY, Martin C, Manuel D, Silver FL, Swartz RH, Tu JV. Rural-urban differences in stroke risk factors, incidence, and mortality in people with and without prior stroke. Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e004973. doi: 10.1161/CIRCOUTCOMES.118.004973

Jarmul J, Pletcher MJ, Hassmiller Lich K, Wheeler SB, Weinberger M, Avery CL, Jonas DE, Earnshaw S, Pignone M. Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of atherosclerotic cardiovascular disease: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004171. doi: 10.1161/CIRCOUTCOMES.117.004171

Emilsson L, Garcia-Albeniz X, Logan RW, Caniglia EC, Kalager M, Hernan MA. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. 2018 Jan 1;4(1):63-70. doi: 10.1001/jamaoncol.2017.2752

Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150

Barrett A, DiBenedetti DB, Rane P, Wade S, Qian Y. Assessing attitudes and treatment preferences among patients with hyperlipidemia: patient focus groups. Poster presented at the AHA QCOR 2017 Scientific Sessions; April 2, 2017. Arlington, VA. [abstract] Circ Cardiovasc Qual Outcomes. 2017 Mar; 10(Suppl 3):A022.

Lupo PJ, Robinson JO, Diamond PM, Jamal L, Danysh HE, Blumenthal-Barby J, Lehmann LS, Vassy JL, Christensen KD, Green RC, McGuire AL, MedSeq Project Team. Patients' perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project. Per Med. 2016 Jan 1;13(1):13-20.

Basch E, Geoghegan C, Coons SJ, Gnanasakthy A, Slagle AF, Papadopoulos EJ, Kluetz PG. Patient-reported outcomes in cancer drug development and US regulatory review perspectives from industry, the Food and Drug Administration, and the patient. JAMA Oncol. 2015 Apr 16. doi: 10.1001/jamaoncol.2015.0530

Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.

Pletcher MJ, Pignone M, Earnshaw SR, McDade CL, Phillips KA, Auer R, Zablotska L, Greenland P. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2014 Mar 1;7(2):276-84. doi: 10.1161/CIRCOUTCOMES.113.000799

Brookhart MA, Wyss MS, Layton JB, Sturmer T. Propensity score methods for confounding control in non-experimental research. Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):604-11. doi: 10.1161/CIRCOUTCOMES.113.000359

Huybrechts KF, Seeger JD, Rothman KJ, Glynn RJ, Avorn J, Schneeweiss S. Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing? Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):e61-4.

Ferreira-Gonzalez I, Marsal JR, Mitjavila F, Parada A, Ribera A, Cascant P, Soriano N, Sanchez PL, Aros F, Heras M, Bueno H, Marrugat J, Cunat J, Civeira E, Permanyer-Miralda G. Patient registries of acute coronary syndrome: assessing or biasing the clinical real world data? Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):540-7. doi: 10.1161/CIRCOUTCOMES.108.844399

Burch SP, Davis KH, Fehnel SE, Nelsen AC, Hill CD, Shashidhar KH. Outcomes, impact and behavior associated with acute treatment of migraine. Poster presented at the 16th Migraine Trust International Symposium; November 2006. [abstract] Cephalalgia. 2006 Nov; 26(11):1358-403.